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Factor Xa Mediates Calcium Flux in 
Endothelial Cells and is Potentiated 
by Igg From Patients With Lupus 
and/or Antiphospholipid Syndrome
Bahar Artim-Esen1,2, Natalia Smoktunowicz3, Thomas McDonnell1, Vera M. Ripoll1, Charis 
Pericleous1,4, Ian Mackie  5, Eifion Robinson6, David Isenberg1, Anisur Rahman1, Yiannis 
Ioannou1, Rachel C. Chambers3 & Ian Giles1
Factor (F) Xa reactive IgG isolated from patients with antiphospholipid syndrome (APS) display higher 
avidity binding to FXa with greater coagulant effects compared to systemic lupus erythematosus (SLE) 
non APS IgG. FXa signalling via activation of protease-activated receptors (PAR) leads to increased 
intracellular calcium (Ca2+). Therefore, we measured alterations in Ca2+ levels in human umbilical 
vein endothelial cells (HUVEC) following FXa-mediated PAR activation and investigated whether FXa 
reactive IgG from patients with APS or SLE/APS- alter these responses. We observed concentration-
dependent induction of Ca2+ release by FXa that was potentiated by APS-IgG and SLE/APS- IgG 
compared to healthy control subjects’ IgG, and FXa alone. APS-IgG and SLE/APS- IgG increased FXa 
mediated NFκB signalling and this effect was fully-retained in the affinity purified anti-FXa IgG sub-
fraction. Antagonism of PAR-1 and PAR-2 reduced FXa-induced Ca2+ release. Treatment with a specific 
FXa inhibitor, hydroxychloroquine or fluvastatin significantly reduced FXa-induced and IgG-potentiated 
Ca2+ release. In conclusion, PAR-1 and PAR-2 are involved in FXa-mediated intracellular Ca2+ release in 
HUVEC and FXa reactive IgG from patients with APS and/or SLE potentiate this effect. Further work is 
required to explore the potential use of IgG FXa reactivity as a novel biomarker to stratify treatment 
with FXa inhibitors in these patients.
Pathogenic antiphospholipid antibodies (aPL) interact with various cells including monocytes, endothelial cells 
(EC) and trophoblast cells leading to the recruitment of cell surface receptors and activation of intracellular 
signalling pathways1. These interactions give rise to the major clinical manifestations of vascular thrombosis 
and/or pregnancy morbidity that define the antiphospholipid syndrome (APS). Evidence has demonstrated the 
importance of inflammation in the pathogenesis of the APS through activation of complement and a family of 
G-protein coupled receptors, protease-activated receptors (PARs)2, 3, four of which (PAR-1-4) have been identi-
fied4. PARs are activated by serine proteinase (SP) enzymes involved in haemostasis5 and inflammation4; includ-
ing thrombin, activated Factor (F) VIIa, FIXa, FXa and FXIIa.
Increased expression of PARs (particularly PAR-2) has been reported in APS monocytes6 and tissue factor 
(TF)/FVIIa/PAR-2 mediated signalling in neutrophils has been shown to be important in the pathogenesis of 
pregnancy morbidity in a murine model of APS3. Furthermore, a panel of monoclonal human aPL displayed 
cross-reactivity with SP, including thrombin, FIXa and FXa7–11 and several monoclonal human aPL inhibited the 
inactivation of procoagulant SP and functional activities of anticoagulant/fibrinolytic SP8, 9, 12, 13. We found that 
amino-acid sequence changes in the antigen binding sites of recombinant human monoclonal aPL which altered 
1Center for Rheumatology Research, Rayne Institute, University College London, London, UK. 2Division of 
Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, 
Turkey. 3Center for Inflammation and Tissue Repair, Rayne Institute, University College London, London, UK. 
4Imperial College London, Kingston upon Thames, United Kingdom. 5Haemostasis Research Unit, Department of 
Haematology, University College London, London, UK. 6Department of Chemistry, Faculty of Maths and Physical 
Sciences, University College London, London, UK. Correspondence and requests for materials should be addressed 
to B.A.-E. (email: bahar.artimesen@istanbul.edu.tr)
Received: 23 March 2017
Accepted: 22 August 2017
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2SCIEnTIFIC REPoRtS | 7: 10788  | DOI:10.1038/s41598-017-11315-9
the pattern of binding to thrombin predicted pathogenicity in mice14. Other studies have identified that between 
13–54% of sera from patients with APS bind different SP9, 12, 15
Therefore, it has been suggested that some aPL may recognise the catalytic domain of SP leading to dysregu-
lation of haemostasis and vascular thrombosis in APS. Given that cellular responses elicited through activation 
of PARs by thrombin and FXa influence pathways responsible for inflammation and haemostasis, modulation of 
PAR activation in the presence of anti-SP antibodies may be important in the pathogenesis of APS. We previously 
showed that thrombin reactive IgG were significantly elevated in patients with APS and in patients with SLE who 
were aPL positive but lacked APS (SLE/aPL+) compared to healthy controls. Furthermore, IgG purified from 
patients with APS displayed higher avidity for thrombin, and significantly inhibited antithrombin-III inactivation 
of thrombin compared with IgG from SLE/aPL+ (without APS) and healthy control subjects (HC)16.
More recently, we have shown that serum from patients with APS and patients with SLE (without APS) had 
significantly increased IgG reactivity for FXa compared with controls17. Polyclonal IgG purified from serum of 
patients with APS showed higher avidity binding to FXa and greater effects upon the enzymatic and coagulant 
activity of FXa compared with polyclonal IgG isolated from patients with SLE who lacked APS. In those experi-
ments, however, we did not study the effects of IgG on the actions exerted by FXa on cells via PARs.
Considering the central position of FXa in the coagulation cascade18 and that FXa acting via PARs influ-
ences inflammation and thrombosis by activating a wide range of cell types including EC19, we hypothesized 
that polyclonal IgG with FXa reactivity may alter these cellular actions in patients with APS and/or SLE. To test 
this hypothesis, we required an experimental system to measure the effects of FXa and IgG on PAR mediated 
activation in EC. Therefore, we measured real-time intracellular calcium (Ca2+) flux, which is widely used to 
measure the activation of G protein coupled receptors such as PARs on various cells. First, we fully characterised 
FXa-PAR mediated alterations in intracellular Ca2+ levels in HUVEC in the absence of IgG and then investigated 
the ability of polyclonal IgG with FXa reactivity isolated from serum of patients with APS or SLE (no APS) to 
alter these FXa-mediated responses. We then measured the functional effects of this FXa reactive IgG and affinity 
purified anti-(a)FXa IgG upon FXa-PAR mediated NFκB signalling in HUVEC. Next we examined the effects 
of a selective FXa inhibitor, antistasin, on the FXa-mediated Ca2+ release in HUVEC in the presence or absence 
of these patient-derived IgG. We also examined the effects of hydroxychloroquine (HCQ) and fluvastatin, since 
these drugs have been proposed to reduce thrombotic risk in APS but whose mechanism of action is unclear and 
for statins has been linked with PAR expression in animal models of APS3.
Results
Clinical and laboratory features of subjects studied. The characteristics of patients and controls are 
shown in Table 1. Of patients with APS, 7 had primary APS and 7 had SLE/APS; whilst 10 had a history of throm-
bosis (6 vascular thrombosis only, 2 vascular thrombosis and pregnancy morbidity and 2 catastrophic APS) and 
4 of pregnancy morbidity only. Of the 14 patients with SLE and no APS (SLE/APS-), 8 were aPL positive (SLE/
aPL+) and 6 aPL negative (SLE/aPL−) with an average disease duration of 19.3 (+/−12.8 SD) years and no APS 
manifestations. Of the five SLE/APS- patients listed as Lupus Anticoagulant (LA) positive, four were weakly pos-
itive once and then negative on repeated testing; only one patient had strong persistent positivity more than 12 
weeks apart. Of these 5 patients: none were positive for anti-β2GPI antibodies; three had single LA positivity; one 
had weak non-persistent aCL positivity; one with strong persistent LA positivity had strong persistent IgM aCL 
positivity; and none have developed any manifestations of APS despite a disease duration ranging from 11–20 
DIAGNOSIS APS (n = 14) SLE/APS- (n = 14) HC (n = 8)
Age, mean years ± SD 45 ± 11 45 ± 13 37 ± 15
Sex, male/female 1/13 2/12 2/6
VT only, n (%) 6 (43) 3(21)* 0
PM only, n (%) 4 (29) 2(14)** 0
VT + PM, n (%) 2 (14) 0 0
CAPS, n (%) 2 (14) 0 0
Other ARD SLE 7 0 0
Manifestations SLE, (n) Muc (6), Haem (7), Joint (7), Ser (2), renal (1), CNS (1)
Joint (13), Haem (11), Ser (8), 
Muc (7), renal (5), CNS (2) —
aCL, mean GPL units 40 ± 31 13 ± 11 8
Anti-β2GPI, mean AU 26 ± 23 12 ± 9 2.5
LA, n (%) 7 (50) 5 (35) 0
Anti-FXa+, mean activity (%)*** 36 ± 18 38 ± 20 0
Anti-Thr+, mean activity (%)*** 17 ± 34 22 ± 19 1.7 ± 3
Table 1. Clinical and laboratory features of patients and controls studied. aCL = Anticardiolipin antibody; 
APS = Antiphospholipid syndrome; ARD = Autoimmune rheumatic disease; ATIII = Antithrombin III; 
AU = Arbitrary units; β2GPI = Anti- β2-glycoprotein I; CAPS = Catastrophic antiphospholipid syndrome; 
CNS = central nervous system; FXa = Factor Xa; GPL = IgG phospholipid; Haem = haematological; 
HC = Healthy control subjects; LA = Lupus anticoagulant; Muc = mucocutaneous; NA = Not available; 
PM = Pregnancy morbidity; SD = Standard deviation; Ser = serositis; SLE = Systemic lupus erythematosus; 
VT = Vascular thrombosis; *SLE/APS- patients with VT were all aPL negative and did not satisfy APS 
classification criteria; **Non-APS miscarriages; ***expressed as percentage binding of a positive control.
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years in these five patients alone. All patients were selected on the basis of their positive binding to FXa. HC 
(n = 8) were randomly chosen from a group of 40 healthy individuals all of whom had no FXa reactive antibodies. 
Purified IgG was used for the experiments.
APS IgG reduces FXa activity. Our previous findings of the effects of APS-IgG on FXa in vitro17 are sum-
marised in Table 2. APS IgG significantly reduced FXa activity (P < 0.0001 for APS versus HC, and P = 0.0008 for 
APS versus SLE IgG) and antithrombin-III mediated inhibition of FXa activity (P < 0.0001 for APS versus SLE 
and APS versus HC IgG) and significantly prolonged the clotting time compared to HC IgG (p < 0.0001) and SLE/
APS- IgG (p = 0.04).
Of the 14 IgG preparations in each APS and SLE/APS- group, 4 in APS and 7 in SLE/APS- displayed weak 
thrombin binding of less than 20% above the threshold for positivity compared with FXa binding which was 
between 40 to 60% above the relative cut-off for positivity (data not shown).
FXa-induced Ca2+ release in HUVEC is attenuated by PAR-1 and PAR-2 antagonists. It was 
important to first fully characterise the kinetics of FXa-PAR-mediated Ca2+ release and the relative contribution 
of PAR-1 and PAR-2 activation in HUVEC. The kinetics of FXa-promoted intracellular Ca2+ secretion in HUVEC 
were different from those of thrombin and PAR-1 and PAR-2 agonist peptide (AP), with a lower magnitude, 
longer lag time and longer duration of action (Fig. 1A to D). Incubation of FXa with Antistasin, a potent, selective 
FXa proteolytic inhibitor caused significant concentration-dependent inhibition of of Ca2+ release: 59% at 25 μM; 
69% at 50 μM; and 70% at 100 μM Antistasin (p < 0.05 at all concentrations compared to FXa alone) (Fig. 2A). 
Antistasin alone did not induce Ca2+ release. Inhibition with the direct thrombin inhibitor Hirudin, did not cause 
a change in the effect of 150 nm FXa on Ca2+ flux, thus confirming that the results were independent of throm-
bin (data not shown). Furthermore, our experiments with 4 different chromogenic substrates to detect FXa and 
thrombin activity in the FXa preparations used showed that FXa had the expected reactivity with substrates hav-
ing greater relative sensitivity and specificity for FXa and no activity on substrates with high thrombin sensitivity. 
All FXa activity was blocked by a high affinity, very specific FXa inhibitor, rivaroxaban, while there was no effect 
of the thrombin inhibitor hirudin (Supplementary data Fig. 1A,B and C). Taken together, these data allowed us 
to conclude that FXa-induces Ca2+ release at high concentrations and that this is dependent on FXa proteolytic 
activity.
We next examined the potential contribution of either PAR-1 or PAR-2 to the FXa-mediated Ca2+ release 
using pharmacological antagonists (RWJ-58259 for PAR-1 and GB83 for PAR-2) and antibodies (ATAP2 for 
PAR-1 and SAM11 for PAR-2). The strongest reduction in FXa-induced Ca2+ release was observed with PAR-1 
inhibition (~60%). PAR-2 inhibition with SAM11 and GB83 also significantly reduced this response (Fig. 2B). In 
contrast, thrombin-induced Ca2+ release was strongly inhibited by PAR-1 antagonism of RWJ-58259 (p < 0.001) 
but no significant reduction was observed with the PAR-2 antagonist, GB83 (Fig. 2C). These studies revealed that 
FXa-mediated Ca2+ release is both PAR-1 and PAR-2 dependent and confirm that Antistasin specifically inhibits 
FXa.
APS-IgG potentiates FXa-mediated intracellular Ca2+ signalling. The effects of polyclonal IgG iso-
lated from patients with APS (n = 14) and FXa reactive antibodies and from patients with SLE/APS- (n = 14) and 
FXa reactive antibodies upon the FXa-PAR interaction were then determined. APS IgG significantly potentiated 
FXa-induced Ca2+ release compared to SLE/APS- IgG (p = 0.02), HC IgG (p < 0.001) and FXa-only stimulation 
(p < 0.001). Significant potentiation of FXa-induced Ca2+ release was also observed with SLE/APS- IgG com-
pared to FXa alone and to HC IgG (p < 0.001 for both) (Fig. 3A). No Ca2+ release was observed by the effect of 
purified IgG on HUVEC in the absence of FXa. To exclude an LA mediated effect between the IgG groups we 
confirmed that SLE/APS-/LA− vs SLE/APS-/LA+ and APS/LA+ vs APS/LA- IgG did not display any significant 
differences (158.2 +/− 17.28 vs 141.1 +/− 9.4 and 242.4 +/− 57 vs 203 +/− 34 respectively). Comparison of 
intracellular Ca2+ release induction by HC IgG to FXa-only stimulation did not reveal any significant difference 
(Fig. 3A). IgG alone did not have an effect upon Ca flux (Fig. 3A).
We then investigated whether the effects of selected IgG (shown as APS1 and APS2) that potently enhanced 
FXa-mediated Ca2+ release were reduced in the presence of the FXa inhibitor. There was a significant reduction 
of IgG-FXa-mediated Ca2+ release in the presence of Antistasin compared to IgG-FXa alone from: 177.4 ± 3.5% 
to 35.74 ± 2.7% (p < 0.0001) for APS1; and 130.8 ± 19.3% to 33.6 ± 4.1% (p = 0.03) for APS2 (Fig. 3B). This APS 
IgG potentiated FXa-induced Ca2+ release was also significantly reduced in the presence of PAR-1 and PAR-2 
antagonists and antibodies (Fig. 3C).
Inhibition of FXa activity 
(mean ± SEM; %)
Inhibition of FXa activity in the 
presence of ATIII* (mean ± SEM; %)
FXa activity –clotting 
time (seconds)
APS-IgG 9.7 ± 0.89 62.03 ± 1.36 74.2 ± 4.4
SLE-IgG 7.07 ± 1.28 81.40 ± 0.32 63.6 ± 2.7
HC-IgG 2.58 ± 0.6 80.16 ± 1.09 26.8 ± 0.6
Table 2. Summary of effects of IgG upon FXa activity in vitro. APS: Antiphospholipid syndrome, AT-III: 
Antithrombin III, HC: Healthy control, SEM: Standard error of mean, SLE: Systemic lupus erythematosus. *All 
compared to FXa-only (without IgG) inhibition by AT-III.
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Hydroxychloroquine and fluvastatin inhibit IgG potentiated FXa-mediated Ca2+ signal-
ling. HCQ and statins have been proposed as potential anti-thrombotic therapies in APS, although the cellular 
mechanisms underlying their anti-thrombotic effects are only partially characterised and for statins have been 
Figure 1. HUVEC response to FXa, thrombin and PAR agonist peptides. Fluo-4 –loaded HUVEC were 
stimulated by PAR-1 and PAR-2 agonists and fluorescence intensity readings recorded continuously for 
10 minutes as described. Data are shown as representative traces of intracellular Ca2+ release upon stimulation 
with (A) Thrombin (10 nM); (B) FXa (150 nM) (C) PAR-1 agonist peptide TFLLR and PAR-2 agonist peptide 
SLIGKV. (D) Concentration-response curves in HUVECs following Thrombin (3–30 nM) and FXa (30–
150 nM) stimulation.
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linked with PAR expression in animal models of APS3. Therefore, we examined whether these drugs may interfere 
with FXa-PAR induced Ca2+ release in HUVEC.
Figure 2. (A) FXa-mediated calcium responses are inhibited by specific FXa inhibitor Antistasin related 
peptide at concentrations 25, 50 and 100 μM. (B) Inhibition of FXa-induced Ca2+ release by PAR inhibitors 
and blocking antibodies. (C) Inhibition of thrombin-induced Ca2+ release by PAR inhibitors and Antistasin. 
Data are plotted with mean ± standard error of mean (SEM), 1-way ANOVA **p < 0.05, ***p < 0.001 when 
compared to FXa alone at all concentrations compared to FXa or thrombin alone. Dotted line represents control 
buffer. ATAP2: PAR-1 blocking antibody; FXa: Factor Xa; GB83: PAR-2 selective antagonist; RWJ–58259: PAR-1 
antagonist; SAM11: PAR-2 blocking antibody, ns: non-significant.
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Figure 3. (A) IgG (used at 200 μg/ml) effect on FXa (150 nM)-induced Ca2+ release. ****p < 0.0001 
when APS-IgG (191.5 ± 11.3%) compared to FXa-only control (78.7 ± 6.9%) and to HC IgG (87.1 ± 3.7%), 
*p = 0.02 when compared to SLE IgG (152.1 ± 11.5%), dotted line represents IgG alone. Each bar represents 
mean ± standard error of mean (SEM) of n = 14 APS IgG, n = 14 SLE IgG and n = 8 HC IgG (B) Antistasin 
inhibited IgG potentiated FXa-calcium mediated responses. IgG that potently inhibited Ca2+ release were 
selected (shown as APS1 and APS2). Comparison of calcium release: by APS1 with inhibited vs unhibited FXa: 
****p < 0.0001, by APS2 with inhibited vs uninhibited FXa: *p = 0.03. Potentiation of FXa-mediated release 
by IgG is also significant: APS1 ***p = 0.0008, APS2 *p = 0.03. Plotted with mean ± SEM (C) Inhibition 
of IgG potentiated FXa-induced Ca2+ release by PAR inhibitors and blocking antibodies. IgG that potently 
inhibited Ca2+ release were selected (shown as APS1 and APS2). ***p = 0.0006 APS1+RWJ-58259 vs APS1, 
**p < 0.05 APS1 + GB83/PAR 1 BL AB/ PAR2 BL AB vs APS1; ****p < 0.0001 APS2+RWJ-58259 vs APS2, 
**p < 0.05 APS1 + GB83/PAR 1 BL AB, *p = 0.01 APS2 + PAR2 BL AB vs APS2; Potentiation of FXa-mediated 
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First, we pre-incubated HUVEC with varying concentrations of HCQ for 20 hours and then untreated 
and treated cells were stimulated with FXa alone. Comparison of FXa stimulation of untreated HUVEC to 
HCQ-treated HUVEC (Fig. 4A) revealed a significant concentration-dependent inhibition of intracellular Ca2+ 
mobilisation from 2.5 μg/ml onwards.
In a separate set of experiments, we pre-incubated cells with different concentrations of fluvastatin for 
20 hours and then untreated and fluvastatin-exposed cells were stimulated with FXa alone. Fluvastatin signifi-
cantly reduced FXa-induced Ca2+ release (p < 0.0001) compared with FXa stimulation of untreated cells (Fig. 4B) 
at all concentrations tested. Cell proliferation assay confirmed viability of cells in the presence of both drugs 
(Supplementary data Fig. 2A and B)
To determine the effect of these drugs on IgG potentiation of FXa-mediated Ca2+ release, the drug treated 
cells were exposed to selected APS IgG (4 samples) that induced the highest Ca2+ release with FXa (Fig. 4C). IgG 
potentiation of FXa induced intracellular Ca2+ release was significantly reduced by: 63% with HCQ (p = 0.01); 
and 57% with Fluvastatin (p = 0.009).
Affinity purified anti-FXa IgG potentiates FXa-mediated intracellular signalling. To confirm that 
the IgG has FXa-PAR mediated effects that are specific to the anti-FXa antibody sub-fraction, anti-(a)FXa IgG 
were afinity purified from n = 3 patients with the highest levels of FXa binding, including both APS and SLE/APS- 
patients. These samples were randomly selected and a limited number tested due to the low yield of IgG from this 
process and ethical restrictions on volume of serum collection. Following purification (Fig. 5A) and elution of 
aFXa IgG we confirmed its binding to FXa (Fig. 5B).
We then measured the functional effects of IgG upon FXa-PAR mediated NFκB signalling in HUVEC as 
previous studies have shown the relevance of this pathway in FXa mediated signalling in EC (Jiang et al., J Surg 
res 2011;169:319 & Bukowska et al., Molecular and Cellular Pharmacology 2013;718:114). We found that aFXa 
IgG upregulated NFκB phosphorylation in the presence of FXa and this effect was fully retained by the affinity 
purified aFXa IgG specific sub-fraction (Fig. 5C and D).
Discussion
In this study we have characterised FXa-PAR-mediated effects on intracellular Ca2+ signalling in HUVEC and 
examined the effects of polyclonal IgG from FXa reactive antibody positive patients with SLE and/or APS, as well 
as HCQ and fluvastatin on this response. We have shown that FXa stimulation of HUVEC is mediated via PAR-1 
and PAR-2 dependent signalling and that this response is enhanced by IgG from FXa reactive antibody positive 
patients with APS as well as SLE/APS- and can be blocked by a specific FXa proteolytic inhibitor, antistasin, HCQ 
and fluvastatin. Furthermore, we developed a method to purify the specific aFXa sub-fraction of these antibodies, 
demonstrated that they fully-retain binding to FXa and have FXa dependent functional effects upon FXa-PAR 
mediated signalling in EC.
Previously, we identified that IgG isolated from FXa reactive antibody positive patients with APS have dif-
ferential avidity and effects upon the enzymatic and coagulant activity of FXa compared with IgG isolated from 
patients with SLE who lacked APS. Given that FXa exerts PAR-mediated cellular effects upon EC and these cells 
are important in the pathogenesis of the APS, we studied the effects of FXa reactive IgG upon FXa activation of 
intracellular Ca2+ signalling responses in EC. PAR activation requires proteolytic cleavage by extracellular pro-
teinases20 to mediate cellular responses. Cleavage of the receptor leads to the intra-molecular binding of a tethered 
ligand and signalling via coupling to G-proteins, and the mobilisation of intracellular Ca2+ 21, 22. EC functions are 
highly dependent on Ca2+ 21 and even minor changes in intracellular Ca2+ can trigger pathological events ranging 
from inflammatory responses to cell death23–26.
Thrombin signalling is well characterised and mediated through PAR-1, 3 and 421. EC express high levels of 
PAR-1 and PAR-2 and the prototypic PAR-1 agonist is thrombin whereas PAR-2 can be activated by a number of 
other proteinases. FXa has been demonstrated to act on PARs in multiple different vascular cell types27, 28. It has 
been shown to activate PAR-229, 30 and PAR-1 on EC and induce Ca2+ responses29, 31, 32. Furthermore, FXa elicits 
protective signalling responses in EC directly via PAR-2 and indirectly via endothelial protein C receptor (EPCR) 
dependent recruitment of PAR-133. Another interesting feature is that different activators of the same receptor 
do not induce identical cellular responses26, 34, 35. A possible explanation for these different cellular responses 
was provided by studies demonstrating that different agonists of PAR1 selectively activate different downstream 
G-protein pathways by their ability to alter receptor/G protein affinity within the same receptor in a process 
known as functional selectivity36.
Therefore, it was initially important to characterise the relative contribution of PAR-1 and PAR-2 to 
FXa-mediated signalling in EC before proceeding to experiments with IgG from patients with FXa reactive anti-
body positive patients.
To achieve this aim, we used agents to specifically inhibit PARs. Two different types of approaches were used: 
monoclonal antibodies which block cleavage of the tethered ligand and thus activation of PAR-1 (ATAP2)37 and 
PAR-2 (SAM11)38; and small molecule antagonist, RWJ-58259, a competitive and reversible PAR-1 antagonist 
that blocks the interaction between the PAR-1 tethered ligand and the second extracellular loop of PAR-139. For 
PAR-2, we used the reversible antagonist, GB8340. We found that inhibition of PAR-1 and PAR-2 receptors by 
release by IgG is significant: APS1 **p = 0.005, APS2 *p = 0.04. Plotted with mean ± standard error of mean. 
APS: Antiphospholipid syndrome; ATAP2: PAR-1 blocking antibody; FXa: Factor Xa; GB83: PAR-2 selective 
antagonist; HC: Healthy control; ns: non-significant; RWJ–58259: PAR-1 antagonist; SAM11: PAR-2 blocking 
antibody; SLE: Systemic lupus erythematosus.
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Figure 4. Effect of drugs on FXa (150 nM)-mediated Ca2+ signaling. Cells were treated with HCQ and 
fluvastatin for 20 hours and stimulated with FXa 150 nM (A) Hydroxychloroquine (HCQ) (used at 1.25, 2.5, 
5, 10 μg/ml) *p = 0.02, **p = 0.001, ***p < 0.001 for comparison of FXa stimulation of untreated cells vs 2.5, 
5, 10 μg/ml HCQ treated HUVEC respectively. (B) Fluvastatin (used at 1.25, 2.5, 5, 10 μM) ****p < 0.0001 for 
comparison of FXa stimulation of untreated cells vs 2.5, 5, 10 μM fluvastatin treated HUVEC respectively.  
(C) Inhibition of IgG-potentiated intracellular Ca2+ release in HCQ 5 μg/ml and fluvastatin 10 μM treated cells. 
IgG that mediated the strongest effect on Ca2+ release was selected. FXa + APS IgG vs FXa-only stimulation 
in untreated cells, *p = 0.03; FXa + APS IgG in untreated cells vs HCQ treated cells, *p = 0.01, vs fluvastatin 
treated cells **p = 0.009. Plotted with mean ± standard error of mean. Dotted line represents drug alone in 
graphs A and B.
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corresponding antagonists and cleavage blocking antibodies caused a significant reduction in FXa-mediated Ca2+ 
release in HUVEC. These findings implicate both PAR-1 and PAR-2 in FXa-mediated signalling.
Having characterised the PAR receptor system involved in FXa signalling in HUVEC, we then examined the 
effects of IgG on this response. We showed that the FXa stimulation of HUVEC in the presence of IgG isolated 
from FXa reactive antibody positive patients with APS caused a significant increase in intracellular Ca2+ release 
compared with SLE/APS- and HC IgG. We believe that these IgG mediated effects may be explained by their 
binding to FXa rather than any cross-reactivity with thrombin for several reasons. First, only 11 of the 28 APS and 
SLE/APS- IgG tested displayed binding to thrombin (which was weak in all 11 cases) in contrast to their strong 
FXa binding seen in all 28 cases. Second, the strongest effect on FXa-mediated Ca2+ release was observed with 
APS IgG, which included only four samples that bound thrombin. Potentiation of Ca2+ release was observed 
with all samples tested whether or not they bound thrombin. Thirdly, this effect was likely to be FXa-mediated 
because it was blocked by Antistasin, a small, disulphide cross-linked protein of 119 amino acid residues, which 
selectively and potently inhibits FXa41. The absence of inhibition by a direct thrombin inhibitor and the lack of 
thrombin activity (using amidolytic substrates) in the FXa preparations also confirm the FXa dependency of the 
effect. Lastly, comparison of LA- IgG to LA+IgG revealed a similar enhancement of FXa-mediated Ca2+ release, 
thus confirming that we did not merely observe a LA effect.
Figure 5. Affinity purification of anti-FXa IgG and effects on FXa-mediated intracellular signaling. The anti-(a)
FXa sub-fraction was affinity purified from n = 3 patients with the hightest FXa binding. (A) Gel showing 
flowthrough of serum passed through the Heparin column (lane 2), wash-step (lane 3), purification through 
aFXa column (lane 4) and subsequent IgG purification by Sepharose protein G (lane 5). (B) A graph showing 
the aFXa activity of IgG fractions: column 1, flow-through of heparin column; column 2, fraction containing 
IgG non-specifically bound to heparin; and column 3, affinity purified aFXa IgG. The values are OD at 450 nm. 
(C) Representative (n = 1) western blot and (D) densitometric analysis (n = 3) showing that FXa reactive whole 
IgG and affinity purified aFXa IgG significantly (p < 0.05) upregulates phosphorylation of NFkB in comparison 
to FXa alone or IgG alone.
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To further study whether these IgG mediated effects were FXa specific we developed a method to affinity 
purify aFXa IgG by passage through a heparin (to remove IgG that binds non-specifically to the negatively 
charged resin) and then FXa column to isolate the aFXa sub-fraction (Fig. 5A). The (n = 3) aFXa IgG tested, 
fully-retained FXa binding (Fig. 5B) and the ability to upregulate FXa mediated NFκB signalling in EC compared 
with the FXa reactive IgG from which it was purified (Fig. 5C and D). We examined these signalling pathways 
because previously studies have shown them to be important in FXa-PAR mediated activation of endothelilal cells 
and human atrial tissue42, 43. The effects of aFXa IgG upon these pathways are directly relevant to our findings with 
FXa reactive IgG upon FXa-mediated Ca2+ release as they represent downstream signalling pathways of FXa-PAR 
activation in EC, thus further evidence that the IgG effects are mediated through binding to FXa.
The yield of IgG from affinity purification is substantially reduced compared to that of whole IgG and does not 
allow for extensive testing in biological assays. For instance, our previous experience with affinity purification of 
the anti-domain (aD)I sub-fraction of IgG the final yield of aDI IgG is appreciably less (140 mcg/ml) compared 
with whole IgG (10–12 mg/ml) so much larger volumes of serum are required to produce the final amount of 
affinity purified IgG for testing of one sample at similar concentrations to whole IgG in functional assays44. In our 
aFXa affinity purification method we obtain similar reductions in yield with final concentrations of aFXa IgG at 
100 mcg/ml. Due to ethical limitations upon the volume of blood collection we were only able to produce limited 
amounts of aFXa IgG for testing in a reduced number of experiments.
The reduced yield obtained with affinity purification of IgG may explain why most other mechanistic studies 
of IgG mediated disease in SLE/APS utilise whole IgG fractions. Of the few studies that carry out affinity purifi-
cation it is usually to test a limited number of samples in validation experiments as we have done. For instance, 
in addition to our own study of n = 1 aDI44 other authors studied effects of: n = 3 affinity purified anti-β2GPI IgG 
onf MyD88 signalling in EC45 n = 6 affinity purified aCL on platelet glycoprotein expression46; and n = 2 affinity 
purified anti-β2GPI antibodies upon in vitro LA activity47. Therefore, we have utilised a well-established method-
ology to study the biological effect of a larger cohort of whole IgG and then confirm the specificity ifs effect using 
a smaller number of affinity purified IgG.
Previously, we have shown that the effects of IgG from patients with primary APS and those with SLE associ-
ated APS on monocyte signalling pathways and the proteome were similar48, 49. Likewise, we did not find a sig-
nificant difference in the effects of IgG from primary APS and SLE/APS- on FXa-mediated Ca2+ release (data not 
shown). Our finding that SLE/APS- IgG also significantly potentiated FXa-mediated Ca2+ release compared to 
HC IgG may indicate that these IgG are also important in SLE. SLE is characterized by an increased risk of cardio-
vascular disease, which is not fully explained by traditional risk factors therefore consideration of immunological 
factors is important50. Given that PAR activation may contribute to the pathogenesis of cardiovascular disease51.
and the central importance of FXa in mediating inflammation and thrombosis via PAR activation, it is tempting 
to speculate that anti-FXa positive IgG may be important in the pathogenesis of cardiovascular disease in SLE.
A direct FXa inhibitor (rivaroxaban) is now widely used as primary and secondary thrombo-prophylaxis in 
several clinical settings. A recent trial has suggested that it may be safely used in the management of patients with 
thrombotic APS and might offer a convenient alternative to warfarin in this subgroup of patients with APS52.
Therefore, our findings of the effect of FXa inhibitors upon in-vitro cellular effects of FXa-reactive APS IgG may 
provide additional evidence to support the use of FXa inhibitors in patients with APS.
In addition, we demonstrated that the FXa-mediated effects of APS-IgG upon EC were inhibited by statins 
and HCQ. The use of these drugs has been proposed in APS to ameliorate the hemorrhagic risk associated with 
anticoagulant drugs. In particular, statins are not only potent inhibitors of cholesterol synthesis but they have also 
been shown to modify the function of EC and platelets by decreasing the expression of adhesion molecules, inhib-
iting TF expression and down-regulating inflammatory cytokines after treatment with aPL53. Simvastatin and 
pravastatin have been shown to decrease TF and PAR-2 expression on neutrophils and prevent pregnancy loss in 
mice3. Similarly, HCQ has been shown to reduce the extent of thrombosis in an animal model of injury-induced 
thrombosis in APS, reverse aPL-induced platelet activation and to protect the EC annexin A5 anticoagulant 
shield from disruption by aPL54. Our new findings provide evidence that these drugs may additionally inhibit the 
biological effect of APS-IgG through their inhibitory effects on FXa-induced Ca2+ release. Interestingly, HCQ has 
been shown to alter Ca2+ signalling in T cells55 and macrophages56 and both of these cells express and respond to 
PAR activation57.
The FXa-mediated potentiation of Ca2+ release in HUVEC by FXa-reactive APS IgG implicates PAR-1 and 
PAR-2 in this endothelial response in the context of APS. To our knowledge there are no published reports of 
APS-related PAR expression in EC. Increased PAR-2 expression has been shown in monocytes isolated from 
patients with thrombotic APS compared with non-thrombotic APS, thrombosis without APS and healthy con-
trols6. This same study also demonstrated a correlation between the levels of PAR-2 expression, aCL IgG titers 
and TF expression in these patients and found that APS-IgG significantly increased expression of PAR-1 and 
PAR-2 on healthy monocytes. Inhibition of PAR-2 prevented the aCL-induced expression of TF6. In addition, 
PAR-2 activation in the TF/FVIIa/PAR-2 complex on neutrophils has been shown to increase neutrophil activa-
tion, trophoblast injury and fetal death in aPL treated mice3. Soluble FXa58 and FXa engaged in the ternary TF/
VIIa/FXa complex59 activate both PAR-1 and PAR-2 leading to cellular effects that are important in modulating 
inflammation, cell survival/proliferation, fibrosis and angiogenesis as well as thrombosis58. PAR activation, may 
therefore, have direct relevance to the pathogenesis of the APS.
The concentration of FXa required to induce intracellular Ca2+ release may appear to be supraphysiologic. 
However, cofactors and biological surfaces exert significant effects on the activity of coagulation factors60. In 
accordance with this FXa signalling is dependent on cell type and cofactor expression61. Its signalling is mediated 
via both PAR1 and PAR2 in endothelial cells but high exogenous concentrations are required for receptor acti-
vation as it is a relatively inefficient activator of PAR129, 61, 62. Additionally, under in vivo conditions, FXa, when 
complexed to TF and FVIIa is five times more potent at activating PAR1 compared to FXa alone which is thought 
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to be related to more efficient recruitment of FXa to the cell membrane62. Furthermore, limited data exist on the 
local concentrations of coagulation factors during pathological states but it is possible that much higher concen-
trations are required at sites of cellular damage and activation.
Although the number of samples in our study may be considered small they are comparable to those of other 
studies that have isolated IgG from patients to examine their biologic effects upon target cells. For instance, 
Cuadrado et al., compared the effects of n = 7 APS IgG with an IgG sample pooled from n = 10 healthy controls 
upon cultured monocytes63; whilst Meroni et al., studied the effects of n = 3 APS-IgG and a healthy control IgG 
on HUVEC signalling mechanisms64. In our systematic review of 29 studies critically analysing the strength of the 
evidence that specific receptors and signalling pathways are important in APS pathogenesis, it was striking that 
APS-IgG samples were obtained from very small numbers (usually five or less) of individual patients65. Therefore, 
the ideal of testing IgG from larger numbers of patients and matched controls remains very difficult for ourselves 
and others to achieve.
In summary we have characterised FXa-PAR mediated activation of EC and found IgG with FXa reactivity 
from patients with APS and SLE/APS to alter it in a PAR-mediated manner. Furthermore, IgG effects are blocked 
by a specific FXa inhibitor as well as HCQ and fluvastatin. Future work is now required to explore whether FXa 
reactivity may allow stratified FXa inhibitory therapy in those patients and further dissect the anti-FXa specificity 
of the effect.
Materials and Methods
Patients and healthy controls. Serum was isolated from selected patients attending University College 
London Hospital with APS, (n = 14) and with SLE and no APS (SLE/APS-), (n = 14) from a larger cohort selected 
on the basis of their positive binding to FXa, and 8 healthy control subjects (HC) who had no FXa reactivity. 
All patients satisfied relevant disease classification criteria – APS66 and SLE67. Informed consent and full ethical 
approval from the local ethics board were obtained (National Research Ethics Committee- London Hampstead, 
reference number 12/LO/0373). All methods were performed in accordance with the relevant guidelines and 
regulations.
Immunologic characterisation and purification of IgG. Coagulation factors were from Haematologic 
Technologies, USA, unless otherwise stated. Porcine gelatin, bovine serum albumin (BSA) and conjugated anti-
bodies were from Sigma-Aldrich, UK. Chromogenic substrates for ELISA were from KPL, USA.
IgG was protein G purified (Pierce, UK), dialysed in phosphate-buffered saline (PBS) and the concentration 
determined by spectrophotometry. Further purification of aFXa IgG was performed by passage of IgG though 
a heparin column to remove IgG that binds non-specifically to the negatively charged resin, followed by purifi-
cation of the remaining IgG fraction though an immobilised FXa column and subsequent dialysis to PBS. The 
presence of IgG directed against cardiolipin14, β2-glycoprotein I (β2-GPI)14 thrombin16 and FXa was measured 
by ELISA as previously described17. The cut-off of positivity for all ELISAs was determined from a cohort of forty 
HC. All samples were tested in duplicate and considered positive when the test optical density (OD) minus the 
background OD exceeded the mean OD + 3 standard deviations (SD) of HC. Results were expressed as percent-
age binding of a positive control.
Clotting and functional assay for FXa activity. Effects of FXa-reactive IgG on FXa-activated clotting 
time (ACT) was measured as described previously17. The effects of anti-FXa reactive IgG on FXa activity were 
studied by digestion of a chromogenic substrate S-2765 (Chromogenix; DiaPharma) both in the absence and 
presence of ATIII and the degree of colour change used to quantify the activity of FXa17.
Human umbilical vein endothelial cells, tissue culture. HUVEC were purchased from Lonza, USA 
and were seeded into 75 cm2 tissue culture flasks (Costar, Cambridge, MA) in EBM-2 basal media (Lonza, USA) 
containing 10% fetal calf serum, L- glutamine, standard antibiotics and endothelial cell growth supplement, 
EGM-2 (Lonza, USA). For calcium signaling experiments, HUVEC of up to passage 4 were trypsinized, seeded 
at a density of 104 cells/well (200 μL/well) in 96-well flat-bottom plates in air containing 5% CO2 at 37 °C and were 
grown to 75% confluency for 48 hours. Cells were serum-starved the night before the experiment and subse-
quently stimulated with FXa under a range of different conditions, as described below.
Measurement of intracellular calcium levels. Intracellular Ca2+ levels were assessed using the Fluo-4 
AM kit (Invitrogen, UK) as described previously68. Briefly, the Ca2+ -binding dye was re-suspended in assay buffer 
(20 mM HEPES in HBSS) supplemented with 2.5 mM probenecid. Cells were loaded with the Ca2+ sensitive dye 
and incubated for 30 minutes at 37 °C and 30 minutes at RT. PAR-1 and PAR-2- mediated changes in intracellu-
lar Ca2+ were monitored using a fluorescent image plate reader (FLIPRTetra, Molecular Devices (UK) Limited, 
Wokingham, UK) following stimulation with 150 nM FXa, 10 nM α-thrombin, 100 μM PAR-1 agonist peptide 
(AP) (TFLLR) or 100 μM PAR-2 AP (SLIGKV) (AP both from Bachem AG, Switzerland)69. The concentrations of 
α-thrombin and PAR-AP were selected based on our previous experience with these agonists in this experimental 
system in EC. The dose of FXa was determined by optimisation experiments.
Experimental conditions. FXa was incubated for 45 minutes with the IgG (200 μg/ml) from patients and 
controls prior to HUVEC stimulation and changes in intracellular Ca2+ release were monitored for 10 minutes 
following stimulation and compared to stimulation with FXa alone. This concentration of IgG was selected 
because it was consistent with the dose used in our previous FXa study17 and is well within the (200–500 μg/ml) 
range used by ourselves and others studying the effects of APS-IgG upon cultured HUVEC70, 71.
The effects of IgG were also measured in the presence of PAR or FXa antagonists or HCQ or fluvastatin. PAR-1 
cleavage-blocking monoclonal antibody (ATAP2)37 and PAR-2 cleavage blocking antibody (SAM11)38 (Santa 
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Cruz Biotechnology, USA) were both used at 10 μg/ml and the selective human PAR-1 antagonist, RWJ – 58259 
(synthesized in-house by the UCL Department of Chemistry)39 was used at 3 µM and a selective PAR-2 antago-
nist, GB83 (Axon Medchem, USA)40 was used at 50 µM. These reagents were added to the cells during the loading 
period, one hour before the experiment. FXa was preincubated with the specific FXa inhibitor Antistasin-Related 
Peptide (D-Arg32) (from Bachem, Germany) at 25, 50 or 100 μM for one hour before it was added to the cells 
to determine the contribution of FXa proteolytic activity. HCQ (used at 1.25, 2.5, 5, 10 μg/ml) and fluvastatin 
(used at 0.1, 0.3, 1, 3 μM; from Sigma-Aldrich, UK), were pre-incubated with cells for 20 hours. Experiments 
were performed at least in triplicate for each condition and data plotted as relative fluorescence units expressed 
in % compared to Ca2+ mobilization in FXa-only stimulated HUVEC. Results are representative of at least three 
independent experiments.
Measurement of intracellular signalling. The effects of aFXa IgG upon FXa mediated EC signalling 
pathways were tested by incubating aFXa IgG (150 µg/ml) with or without FXa (40 nM) for 30 minutes before 
stimulating HUVEC in 10% FCS-EGM media. Cell lysates were obtained at 20 and 40 minutes to measure phos-
phorylated & total forms of NFkB.
Statistical analysis of data. Data are presented as means ± SEM and were analysed in GraphPad Prism 
using ANOVA (multiple group comparisons) followed by Tukey HSD post hoc analysis or Student’s t-test (single 
group comparisons). Differences between means with a p-value < 0.05 were considered significant.
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